Compare PZZA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | NNNN |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1993 | 2025 |
| Metric | PZZA | NNNN |
|---|---|---|
| Price | $37.86 | $32.20 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $49.44 | N/A |
| AVG Volume (30 Days) | ★ 685.3K | 33.4K |
| Earning Date | 02-26-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | 0.06 |
| Revenue | ★ $2,086,399,000.00 | $6,920,153.00 |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $32.99 | $584.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.16 | $5.18 |
| 52 Week High | $55.74 | $55.65 |
| Indicator | PZZA | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 53.52 |
| Support Level | $38.10 | $27.32 |
| Resistance Level | $40.50 | $35.45 |
| Average True Range (ATR) | 1.15 | 3.97 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 15.20 | 53.09 |
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.